BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19705067)

  • 1. Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival.
    McBride SM; Perez DA; Polley MY; Vandenberg SR; Smith JS; Zheng S; Lamborn KR; Wiencke JK; Chang SM; Prados MD; Berger MS; Stokoe D; Haas-Kogan DA
    J Neurooncol; 2010 Mar; 97(1):33-40. PubMed ID: 19705067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.
    Mueller S; Phillips J; Onar-Thomas A; Romero E; Zheng S; Wiencke JK; McBride SM; Cowdrey C; Prados MD; Weiss WA; Berger MS; Gupta N; Haas-Kogan DA
    Neuro Oncol; 2012 Sep; 14(9):1146-52. PubMed ID: 22753230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal transduction molecules in gliomas of all grades.
    Ermoian RP; Kaprealian T; Lamborn KR; Yang X; Jelluma N; Arvold ND; Zeidman R; Berger MS; Stokoe D; Haas-Kogan DA
    J Neurooncol; 2009 Jan; 91(1):19-26. PubMed ID: 18759130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes
    Makker A; Goel MM; Mahdi AA; Bhatia V; Das V; Agarwal A; Pandey A
    Indian J Med Res; 2016 May; 143(Supplement):S112-S119. PubMed ID: 27748285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.
    Xu G; Zhang W; Bertram P; Zheng XF; McLeod H
    Int J Oncol; 2004 Apr; 24(4):893-900. PubMed ID: 15010827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.
    Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ
    J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases.
    Adamo B; Deal AM; Burrows E; Geradts J; Hamilton E; Blackwell KL; Livasy C; Fritchie K; Prat A; Harrell JC; Ewend MG; Carey LA; Miller CR; Anders CK
    Breast Cancer Res; 2011; 13(6):R125. PubMed ID: 22132754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.
    Wahl M; Chang SM; Phillips JJ; Molinaro AM; Costello JF; Mazor T; Alexandrescu S; Lupo JM; Nelson SJ; Berger M; Prados M; Taylor JW; Butowski N; Clarke JL; Haas-Kogan D
    Cancer; 2017 Dec; 123(23):4631-4639. PubMed ID: 28759109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer.
    Chun SH; Jung CK; Won HS; Kang JH; Kim YS; Kim MS
    Head Neck; 2015 May; 37(5):636-43. PubMed ID: 24616007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K/AKT pathway activation in bladder carcinogenesis.
    Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
    Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis.
    Yang J; Liao D; Wang Z; Liu F; Wu G
    J Surg Res; 2011 Jun; 168(1):97-102. PubMed ID: 20036387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.
    Zhang X; Wu Y; Sun X; Cui Q; Bai X; Dong G; Gao Z; Wang Y; Gao C; Sun S; Ji N; Liu Y
    BMC Cancer; 2022 Feb; 22(1):190. PubMed ID: 35184749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-17 targets PTEN and facilitates glial scar formation after spinal cord injuries via the PI3K/Akt/mTOR pathway.
    Luan Y; Chen M; Zhou L
    Brain Res Bull; 2017 Jan; 128():68-75. PubMed ID: 27693649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
    Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
    Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma.
    Pópulo H; Soares P; Rocha AS; Silva P; Lopes JM
    Melanoma Res; 2010 Apr; 20(2):107-17. PubMed ID: 20173664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.
    Chakravarti A; Zhai G; Suzuki Y; Sarkesh S; Black PM; Muzikansky A; Loeffler JS
    J Clin Oncol; 2004 May; 22(10):1926-33. PubMed ID: 15143086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
    Thoury A; Descatoire V; Kotelevets L; Kannengiesser C; Bertrand G; Theou-Anton N; Frey C; Genestie C; Raymond E; Chastre E; Lehy T; Walker F
    Histol Histopathol; 2014 Nov; 29(11):1455-66. PubMed ID: 24811063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combination of genetic and biochemical analyses for the diagnosis of PI3K-AKT-mTOR pathway-associated megalencephaly.
    Negishi Y; Miya F; Hattori A; Johmura Y; Nakagawa M; Ando N; Hori I; Togawa T; Aoyama K; Ohashi K; Fukumura S; Mizuno S; Umemura A; Kishimoto Y; Okamoto N; Kato M; Tsunoda T; Yamasaki M; Kanemura Y; Kosaki K; Nakanishi M; Saitoh S
    BMC Med Genet; 2017 Jan; 18(1):4. PubMed ID: 28086757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs).
    Li J; Dang Y; Gao J; Li Y; Zou J; Shen L
    Med Oncol; 2015 Apr; 32(4):111. PubMed ID: 25757539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.